188 related articles for article (PubMed ID: 20217129)
1. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Chang H; Rha SY; Jeung HC; Jung JJ; Kim TS; Kwon HJ; Kim BS; Chung HC
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1901-13. PubMed ID: 20217129
[TBL] [Abstract][Full Text] [Related]
2. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Chang H; Jeung HC; Jung JJ; Kim TS; Rha SY; Chung HC
Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
6. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.
Lu H; Yang XF; Tian XQ; Tang SL; Li LQ; Zhao S; Zheng HC
Oncotarget; 2016 Aug; 7(35):56508-56525. PubMed ID: 27447743
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
8. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
12. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma.
Zhao J; Li QQ; Zou B; Wang G; Li X; Kim JE; Cuff CF; Huang L; Reed E; Gardner K
Int J Oncol; 2007 Aug; 31(2):241-52. PubMed ID: 17611679
[TBL] [Abstract][Full Text] [Related]
13. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS
J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
15. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
17. 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Clinckspoor I; Verlinden L; Overbergh L; Korch C; Bouillon R; Mathieu C; Verstuyf A; Decallonne B
J Steroid Biochem Mol Biol; 2011 Mar; 124(1-2):1-9. PubMed ID: 21182945
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Liao B; Liang H; Chen J; Liu Q; Zhang B; Chen X
Tumour Biol; 2015 Dec; 36(12):9347-56. PubMed ID: 26108995
[TBL] [Abstract][Full Text] [Related]
19. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
20. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Qin Y; Zhao X; Fang Y
Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]